Charles Zhu
Stock Analyst at LifeSci Capital
(2.77)
# 1,951
Out of 4,915 analysts
25
Total ratings
54.55%
Success rate
21.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $12.42 | +77.13% | 1 | Jun 18, 2025 | |
| RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $1.51 | - | 1 | Dec 13, 2024 | |
| TNGX Tango Therapeutics | Maintains: Buy | $18 → $8 | $6.04 | +32.45% | 3 | Nov 7, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.56 | +669.23% | 4 | Nov 7, 2023 | |
| MRUS Merus | Maintains: Buy | $46 → $48 | $66.24 | -27.54% | 6 | Aug 8, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $78.41 | -28.58% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $3.10 | +609.68% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $11.42 | +127.67% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $24.35 | +31.42% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $12.57 | +11.38% | 2 | May 5, 2022 |
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $12.42
Upside: +77.13%
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.51
Upside: -
Tango Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $18 → $8
Current: $6.04
Upside: +32.45%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.56
Upside: +669.23%
Merus
Aug 8, 2023
Maintains: Buy
Price Target: $46 → $48
Current: $66.24
Upside: -27.54%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $78.41
Upside: -28.58%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $3.10
Upside: +609.68%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $11.42
Upside: +127.67%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $24.35
Upside: +31.42%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $12.57
Upside: +11.38%